Comparison · NCT00217022-8d5cbfe8
Budesonide vs Placebo: Satisfactory Control of Diarrhea During at Least Three of the Last Four Weeks
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Budesonide vs Placebo: Satisfactory Control of Diarrhea During at Least Three of the Last Four Weeks. Trial comparisons, record NCT00217022-8d5cbfe8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00217022-8d5cbfe8
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.741 | 1 | wilson | |
| Risk in group 2 | 1 | 0.51 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.259 | 0.49 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 1 | 1 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Budesonide | 9 mg daily | 11 | 11 | OG000 |
| Group 2 | Placebo | three tablets daily | 4 | 4 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Satisfactory Control of Diarrhea During at Least Three of the Last Four Weeks
- Description
Subjects were asked if they felt they had satisfactory control of their diarrhea, along with the number of stools and type of stool (loose, water, formed, hard) the patient were experiencing. The rating of satisfactory control of diarrhea was therefore a partially subjective measure. This outcome measure was to be recorded for three out of the last four weeks that a subject was on the study; subjects were to take part in the study approximately 8 weeks.
- Time frame
- Three out of last four weeks that the subject was on the study
- Population
Source ClinicalTrials.gov
Trial
- Title
- Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis
- NCT number
- NCT00217022
- Phases
- PHASE2, PHASE3
- Conditions
- Lymphocytic Colitis, Diarrhea
- Interventions
- Placebo, Budesonide
- Lead sponsor
- Mayo Clinic
- Results first posted
- 2012-04-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00217022?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00217022-8d5cbfe8